Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis

BACKGROUND: BUP-XR (RBP-6000 or SUBLOCADE) is the first Food and Drug Administration–approved subcutaneously administered monthly extended-release buprenorphine medication for the treatment of moderate or severe opioid use disorder. The primary objective of this phase III study was to assess the lon...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Psychopharmacol
Autores principales: Andorn, Anne C., Haight, Barbara R., Shinde, Sunita, Fudala, Paul J., Zhao, Yue, Heidbreder, Christian, Learned, Susan M., Fox, Norma Lynn, Nadipelli, Vijay R., Hassman, David, Rutrick, Daniel
Formato: Artigo
Lenguaje:Inglês
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Contributions
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188268/
https://ncbi.nlm.nih.gov/pubmed/32282418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0000000000001195
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares